Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones

Cytotherapy

Volumn 4, Issue 5, 2002, Pages 443-444

  Jensen, Michael C ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; B CELL LYMPHOMA; CELL CLONE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DNA VECTOR; GENE PROBE; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA; NONHUMAN; PROMOTER REGION; T LYMPHOCYTE; ANIMAL; B LYMPHOCYTE; BLOOD DISEASE; CELL CULTURE; CHEMISTRY; IMMUNOLOGY; LYMPHOMA; METABOLISM; REVIEW;

ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; GENE TRANSFER TECHNIQUES; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; LYMPHOMA; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036436402     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402320776125     Document Type: Conference Paper

References (3)

1. + malignancy. Biol Blood Marrow Transplant 1998;4:75-83.
2. Jensen MC, Clarke P, Tan G et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther 2000;1:49-55.
3. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-41.